450 Eli Lilly and Company $LLY Shares Purchased by Vigilare Wealth Management

Vigilare Wealth Management grew its stake in Eli Lilly and Company (NYSE:LLY) by 32.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,819 shares of the company’s stock after buying an additional 450 shares during the period. Vigilare Wealth Management’s holdings in Eli Lilly and Company were worth $2,106,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in LLY. Welch Group LLC increased its position in Eli Lilly and Company by 6.9% during the 3rd quarter. Welch Group LLC now owns 16,100 shares of the company’s stock valued at $18,629,000 after purchasing an additional 1,036 shares during the period. Trek Financial LLC raised its holdings in Eli Lilly and Company by 10.3% during the 3rd quarter. Trek Financial LLC now owns 4,059 shares of the company’s stock worth $4,697,000 after purchasing an additional 380 shares during the last quarter. Woodmont Investment Counsel LLC lifted its position in shares of Eli Lilly and Company by 1.3% in the 3rd quarter. Woodmont Investment Counsel LLC now owns 22,467 shares of the company’s stock worth $25,997,000 after purchasing an additional 284 shares during the period. Traynor Capital Management Inc. lifted its position in shares of Eli Lilly and Company by 1.1% in the 3rd quarter. Traynor Capital Management Inc. now owns 55,402 shares of the company’s stock worth $64,104,000 after purchasing an additional 588 shares during the period. Finally, Walled Lake Planning & Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 12.9% in the 3rd quarter. Walled Lake Planning & Wealth Management LLC now owns 641 shares of the company’s stock worth $742,000 after purchasing an additional 73 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Citigroup increased their price objective on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a research report on Friday. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a research note on Friday. Guggenheim boosted their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a report on Friday, September 18th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Argus increased their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,404.14.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Another strong quarter and higher guidance: Third-quarter revenue rose roughly 39% year over year to $24.4 billion, beating expectations, while adjusted EPS also exceeded estimates. Strong demand for Mounjaro and Zepbound led Lilly to raise its full-year outlook. Eli Lilly Just Delivered Another Blowout Quarter
• Positive Sentiment: Analyst price-target increases: Cantor Fitzgerald raised its target to $1,600 and maintained an “overweight” rating. Other firms, including JPMorgan, also boosted targets, reflecting continued confidence in Lilly’s earnings outlook. Cantor Fitzgerald price target
• Neutral Sentiment: Commercial reorganization: Lilly is combining its U.S. and international commercial operations into one division. The move could improve coordination and execution globally, but its financial effect is not yet clear. Lilly combines commercial divisions
• Negative Sentiment: Pricing and growth concerns: Medicare’s GLP-1 Bridge program and lower realized drug prices may pressure revenue and margins. Analysts also warn that growth could moderate after exceptionally strong results, while one-time revenue benefits may not recur. Lilly’s First Full Medicare Quarter
• Negative Sentiment: High expectations and concentration risk: With about two-thirds of revenue tied to its leading GLP-1 medicines and the shares trading at a premium valuation, investors may be taking profits and demanding evidence that rapid growth can continue. Eli Lilly: Softer Growth Ahead

Eli Lilly and Company Trading Down 0.4%

Shares of LLY stock opened at $1,412.06 on Tuesday. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,449.68. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a 50 day simple moving average of $1,200.81 and a two-hundred day simple moving average of $1,094.25. The company has a market cap of $1.33 trillion, a P/E ratio of 45.83, a PEG ratio of 1.73 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period in the prior year, the business earned $7.02 EPS. Research analysts forecast that Eli Lilly and Company will post 35.18 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is presently 22.46%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 in the last quarter. Company insiders own 0.14% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.